Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367017574> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W4367017574 endingPage "15" @default.
- W4367017574 startingPage "15" @default.
- W4367017574 abstract "Abata Therapeutics has launched with $95 million in series A funding to take cell therapy into a new realm: the treatment of multiple sclerosis. The investment comes primarily from Third Rock Ventures. ElevateBio, which specializes in manufacturing cell therapies , has also invested and is helping Abata develop its production process. The company started quietly 3 years ago and is still in preclinical stages. Abata’s technology involves regulatory T cells (T regs), immune cells that tamp down immune activity. Abata is one of several companies investigating how to manipulate these cells to treat the immune overreaction that characterizes inflammatory and autoimmune diseases. “They’re essentially the ideal therapy for an autoimmune disease,” Abata CEO Samantha Singer says about T regs. “They can promote repair as well as stop tissue destruction, and they last a long time.” Abata’s primary disease target is multiple sclerosis in people who have nonrelapsing disease. Current MS" @default.
- W4367017574 created "2023-04-27" @default.
- W4367017574 creator A5055911861 @default.
- W4367017574 date "2021-06-28" @default.
- W4367017574 modified "2023-09-23" @default.
- W4367017574 title "Abata launches with $95 million in funding" @default.
- W4367017574 doi "https://doi.org/10.1021/cen-09924-buscon5" @default.
- W4367017574 hasPublicationYear "2021" @default.
- W4367017574 type Work @default.
- W4367017574 citedByCount "0" @default.
- W4367017574 crossrefType "journal-article" @default.
- W4367017574 hasAuthorship W4367017574A5055911861 @default.
- W4367017574 hasConcept C126322002 @default.
- W4367017574 hasConcept C144133560 @default.
- W4367017574 hasConcept C17744445 @default.
- W4367017574 hasConcept C199539241 @default.
- W4367017574 hasConcept C203014093 @default.
- W4367017574 hasConcept C27548731 @default.
- W4367017574 hasConcept C2776639384 @default.
- W4367017574 hasConcept C2778757428 @default.
- W4367017574 hasConcept C2779134260 @default.
- W4367017574 hasConcept C2780640218 @default.
- W4367017574 hasConcept C71924100 @default.
- W4367017574 hasConcept C8891405 @default.
- W4367017574 hasConcept C94625758 @default.
- W4367017574 hasConceptScore W4367017574C126322002 @default.
- W4367017574 hasConceptScore W4367017574C144133560 @default.
- W4367017574 hasConceptScore W4367017574C17744445 @default.
- W4367017574 hasConceptScore W4367017574C199539241 @default.
- W4367017574 hasConceptScore W4367017574C203014093 @default.
- W4367017574 hasConceptScore W4367017574C27548731 @default.
- W4367017574 hasConceptScore W4367017574C2776639384 @default.
- W4367017574 hasConceptScore W4367017574C2778757428 @default.
- W4367017574 hasConceptScore W4367017574C2779134260 @default.
- W4367017574 hasConceptScore W4367017574C2780640218 @default.
- W4367017574 hasConceptScore W4367017574C71924100 @default.
- W4367017574 hasConceptScore W4367017574C8891405 @default.
- W4367017574 hasConceptScore W4367017574C94625758 @default.
- W4367017574 hasIssue "24" @default.
- W4367017574 hasLocation W43670175741 @default.
- W4367017574 hasOpenAccess W4367017574 @default.
- W4367017574 hasPrimaryLocation W43670175741 @default.
- W4367017574 hasRelatedWork W105452435 @default.
- W4367017574 hasRelatedWork W2096287500 @default.
- W4367017574 hasRelatedWork W2111785400 @default.
- W4367017574 hasRelatedWork W2348697133 @default.
- W4367017574 hasRelatedWork W2362085610 @default.
- W4367017574 hasRelatedWork W2372121539 @default.
- W4367017574 hasRelatedWork W2377974984 @default.
- W4367017574 hasRelatedWork W2383049857 @default.
- W4367017574 hasRelatedWork W2617222556 @default.
- W4367017574 hasRelatedWork W267936491 @default.
- W4367017574 hasVolume "99" @default.
- W4367017574 isParatext "false" @default.
- W4367017574 isRetracted "false" @default.
- W4367017574 workType "article" @default.